These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 34075667)
1. Topical beta-blockers in dermatologic therapy. Filoni A; Ambrogio F; De Marco A; Pacifico A; Bonamonte D Dermatol Ther; 2021 Jul; 34(4):e15016. PubMed ID: 34075667 [TBL] [Abstract][Full Text] [Related]
2. Beta-Blockers for Pyogenic Granuloma: A Systematic Review of Case Reports, Case Series, and Clinical Trials. Dany M J Drugs Dermatol; 2019 Oct; 18(10):1006-1010. PubMed ID: 31584779 [TBL] [Abstract][Full Text] [Related]
3. Are topical beta-blockers really effective "in real life" for targeted therapy-induced paronychia. Sibaud V; Casassa E; D'Andrea M Support Care Cancer; 2019 Jul; 27(7):2341-2343. PubMed ID: 30847700 [TBL] [Abstract][Full Text] [Related]
4. Topical timolol in dermatology: infantile haemangiomas and beyond. Alzaid M; Al-Naseem A; Al-Niaimi F; Ali FR Clin Exp Dermatol; 2022 May; 47(5):819-832. PubMed ID: 34798680 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. Sollena P; Mannino M; Tassone F; Calegari MA; D'Argento E; Peris K Drugs Context; 2019; 8():212613. PubMed ID: 31798664 [TBL] [Abstract][Full Text] [Related]
6. Treatment of pediatric pyogenic granulomas using β-adrenergic receptor antagonists. Wine Lee L; Goff KL; Lam JM; Low DW; Yan AC; Castelo-Soccio L Pediatr Dermatol; 2014; 31(2):203-7. PubMed ID: 24138457 [TBL] [Abstract][Full Text] [Related]
11. Timolol for the treatment of pyogenic granuloma (PG) in children. Knöpfel N; Escudero-Góngora MDM; Bauzà A; Martín-Santiago A J Am Acad Dermatol; 2016 Sep; 75(3):e105-e106. PubMed ID: 27543231 [No Abstract] [Full Text] [Related]
12. A pyogenic granuloma treated with topical timolol. Malik M; Murphy R Br J Dermatol; 2014 Dec; 171(6):1537-8. PubMed ID: 24836966 [TBL] [Abstract][Full Text] [Related]
13. Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events. Yoon DJ; Kaur R; Gallegos A; West K; Yang H; Schaefer S; Tchanque-Fossuo C; Dahle SE; Isseroff RR Am J Clin Dermatol; 2021 Jan; 22(1):89-99. PubMed ID: 33237496 [TBL] [Abstract][Full Text] [Related]
17. Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis. Ovadia SA; Landy DC; Cohen ER; Yang EY; Thaller SR Ann Plast Surg; 2015 Feb; 74(2):256-62. PubMed ID: 25590249 [TBL] [Abstract][Full Text] [Related]
18. Topical Timolol for Infantile Hemangiomas: Evidence for Efficacy and Degree of Systemic Absorption. Weibel L; Barysch MJ; Scheer HS; Königs I; Neuhaus K; Schiestl C; Rentsch K; Müller DM; Theiler M Pediatr Dermatol; 2016; 33(2):184-90. PubMed ID: 26840644 [TBL] [Abstract][Full Text] [Related]
19. Review of topical beta blockers as treatment for infantile hemangiomas. Painter SL; Hildebrand GD Surv Ophthalmol; 2016; 61(1):51-8. PubMed ID: 26408055 [TBL] [Abstract][Full Text] [Related]
20. The role of topical timolol in wound healing and the treatment of vascular lesions: A narrative review. Goodarzi A; Mozafarpoor S; Dodangeh M; Seirafianpour F; Shahverdi MH Dermatol Ther; 2021 Mar; 34(2):e14847. PubMed ID: 33538017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]